Friday 6 November 2026
Export PBH’s income statement to Excel — free account
Prestige Consumer Healthcare Inc.
PBH Healthcare Drug Manufacturers Specialty & Generic
Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025.
- Revenue
- +22.7%
- EPS
- −38.4%
- Free cash flow
- −38.2%
- Total debt
- +100.9%
Quarter to September 2026, against a year earlier
43.42
0.90
−2.03%
Follow PBH
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| 8.23% | 9.12% | 10.22% | 10.31% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
5 | 4 | 5 | 5 | |
| 3.80% | 4.30% | 5.52% | 5.47% | ||
ROIC |
9.59% | 4.70% | 6.82% | 7.15% | |
Return on Tangible Assets |
35.21% | 37.38% | 44.03% | 44.19% | |
Average Days of Receivables |
76.35 | 61.89 | 64.34 | 62.99 | |
Free Cash Flow per Share |
4.51 | 4.96 | 5.09 | 5.58 | |
Free Cash Flow |
214.22 | 235.36 | 246.45 | 267.19 | |
Capital Expenditures |
(15.56) | (14.04) | (11.18) | (9.45) | |
| Other line items | |||||
Cash ROIC |
10.76% | 5.82% | 8.32% | 9.08% | |
Accounts Receivable Turnover |
5.27 | 6.21 | 5.64 | 6.17 | |
Accounts Payable Turnover |
12.91 | 17.39 | 23.64 | 15.51 | |
Inventory Turnover |
3.28 | 2.99 | 3.21 | 3.07 | |
Average Days of Payables |
28.97 | 26.20 | 16.87 | 32.37 | |
Days of Inventory on Hand |
117.92 | 135.22 | 117.79 | 123.29 | |
Tax Rate |
(0.27) | (0.27) | (0.26) | (0.30) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
25.38% | 25.32% | 24.36% | 23.91% | |
Share Based Compensation of Revenue |
0.91% | 1.01% | 1.00% | 0.99% | |
Interest Coverage |
— | 6.30 | 7.31 | 7.74 | |
Operating CF/Net income |
1.48 | 1.45 | 1.35 | 1.48 | |
Depreciation/Fixed assets |
0.34 | 0.29 | 0.27 | 0.25 | |
Capex/Depreciation |
(0.39) | (0.41) | (0.34) | (0.30) | |
Revenue per Share |
24.57 | 23.28 | 22.47 | 23.05 | |
Operating CF per Share |
4.84 | 5.25 | 5.32 | 5.78 | |
Capex per Share |
(0.33) | (0.30) | (0.23) | (0.20) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 |
Columns are period end dates · fundamentals updated 5 Nov 2026